Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2011

Oxford Medical Diagnostics to Offer V&F Mass Spec Technology in the U.K. and Ireland

  • Oxford Medical Diagnostics (OMD) will offer and support V&F Analyse- und Messtechnik high-performance mass spectrometry analyzers in the U.K. and Ireland. OMD will also establish a contract batch sample analysis service in its Oxford laboratories to provide analytical services to third-party customers using V&F’s mass spectrometers.

    In addition, the companies are looking into other opportunities for joint research. These include bacterial headspace analysis—analyzing the space above bacteriological samples such as MRSA and Clostridium difficile—as well as sports-performance monitoring and healthy weight-loss management.

    OMD already uses V&F’s mass spectrometry technology to compare clinical results from diabetic patients with its laser-based breath-analysis solutions. The company, a spin-out from the University of Oxford, is focused on noninvasive diagnostic breath analysis. It is developing the Acetone Breath Analyzer, an infrared absorption spectroscopy analyzer designed to screen and diagnose type 1 and type 2 diabetes by detecting acetone in the patient’s breath.

    V&F has designed and manufactured mass spectrometers for real-time gas analysis based on its Ion Molecule Reaction Mass Spectrometry technology. In the U.S., V&F distributes its mass spectrometers through wholly owned subsidiaries, V&F Instruments, and V&F Gas Analysis Systems.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »